AXOFT RAISES $55M, TESTS BRAIN IMPLANT IN CHINA

Axoft, a Boston-based medical device company, announced the Series A funding round as it expands clinical testing of its brain implant technology internationally. The company has already implanted its device in a Shanghai patient, marking an early step in establishing a clinical presence in China. The funding round underscores investor confidence in Axoft's technology at a time when brain-computer interfaces are attracting significant capital. The company joins a growing field of neurotechnology firms developing implants designed to restore motor and sensory function in patients with neurological conditions. Axoft's decision to pursue trials in China represents a notable development amid broader US-China tensions in technology sectors. Brain implant technology typically faces regulatory scrutiny, making international clinical trials complex. The company's ability to conduct testing in Shanghai suggests it has navigated Chinese regulatory pathways and secured necessary approvals. The company has outlined plans for expanded trials in China, though specific timelines and patient populations remain unclear. Details about the Shanghai trial—including the patient's condition, implant specifications, and outcomes—have not been disclosed. Brain implant technology has advanced significantly in recent years. Neuralink, Elon Musk's neurotechnology venture, received FDA approval for human trials in 2023. Other competitors include BrainGate and various academic institutions developing similar systems. Axoft's international expansion strategy differs from some US competitors who have focused primarily on domestic regulatory approval. The company's willingness to pursue simultaneous trials across jurisdictions could accelerate data collection and product development, though it adds operational complexity. The $55 million Series A will likely fund continued trial expansion, regulatory submissions, and technology refinement. As brain implant companies mature, access to diverse patient populations and regulatory environments becomes increasingly valuable for demonstrating safety and efficacy across different populations.